Francesca Tamarozzi1, Tamara Ursini1, Pytsje T Hoekstra2, Ronaldo Silva1, Cecilia Costa3, Federico Gobbi1, Gerardo B Monteiro1, Leonardo Motta4, Govert J van Dam2, Paul L Corstjens5, Lisette van Lieshout2, Dora Buonfrate6. 1. Department of Infectious-Tropical Diseases and Microbiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Sacro Cuore Don Calabria Hospital, Viale Luigi Rizzardi 4, 37024, Negrar di Valpolicella, Verona, Italy. 2. Department of Parasitology, Leiden University Medical Centre, Leiden, The Netherlands. 3. Dipartimento medico di malattie infettive, Ospedale Maggiore della Carità, Novara, Italy. 4. Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 5. Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Infectious-Tropical Diseases and Microbiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Sacro Cuore Don Calabria Hospital, Viale Luigi Rizzardi 4, 37024, Negrar di Valpolicella, Verona, Italy. dora.buonfrate@sacrocuore.it.
Abstract
BACKGROUND: An accurate test for the diagnosis and post-treatment follow-up of patients with schistosomiasis is needed. We assessed the performance of different laboratory parameters, including the up-converting reporter particle technology lateral flow assay to detect circulating anodic antigen (UCP-LF CAA), for the post-treatment follow-up of schistosomiasis in migrants attending a dedicated outpatient clinic in a non-endemic country. METHODS: Routine anti-Schistosoma serology results and eosinophil counts were obtained of patients with positive urine/stool microscopy and/or PCR (confirmed cases) or only positive serology (possible cases), and at least one follow-up visit at 6 (T6) or 12 (T12) months after praziquantel treatment. All sera samples were tested with the UCP-LF CAA assay. RESULTS: Forty-eight patients were included, 23 confirmed and 25 possible cases. The percentage seropositivity and median antibody titers did not change significantly during follow-up. UCP-LF CAA was positive in 86.9% of confirmed and 20% of possible cases. The percentage positivity and median CAA levels decreased significantly post-treatment, with only two patients having positive CAA levels at T12. CONCLUSIONS: The UCP-LF CAA assay proved useful for the diagnosis of active infection with Schistosoma spp. and highly valuable for post-treatment monitoring in migrants, encouraging the development of a commercial test.
BACKGROUND: An accurate test for the diagnosis and post-treatment follow-up of patients with schistosomiasis is needed. We assessed the performance of different laboratory parameters, including the up-converting reporter particle technology lateral flow assay to detect circulating anodic antigen (UCP-LF CAA), for the post-treatment follow-up of schistosomiasis in migrants attending a dedicated outpatient clinic in a non-endemic country. METHODS: Routine anti-Schistosoma serology results and eosinophil counts were obtained of patients with positive urine/stool microscopy and/or PCR (confirmed cases) or only positive serology (possible cases), and at least one follow-up visit at 6 (T6) or 12 (T12) months after praziquantel treatment. All sera samples were tested with the UCP-LF CAA assay. RESULTS: Forty-eight patients were included, 23 confirmed and 25 possible cases. The percentage seropositivity and median antibody titers did not change significantly during follow-up. UCP-LF CAA was positive in 86.9% of confirmed and 20% of possible cases. The percentage positivity and median CAA levels decreased significantly post-treatment, with only two patients having positive CAA levels at T12. CONCLUSIONS: The UCP-LF CAA assay proved useful for the diagnosis of active infection with Schistosoma spp. and highly valuable for post-treatment monitoring in migrants, encouraging the development of a commercial test.
Authors: Agnese Comelli; Niccolò Riccardi; Diana Canetti; Michele Spinicci; Giovanni Cenderello; Paola Magro; Laura Ambra Nicolini; Valentina Marchese; Lorenzo Zammarchi; Francesco Castelli; Alessandro Bartoloni; Antonio Di Biagio; Silvio Caligaris; Giovanni Gaiera Journal: J Travel Med Date: 2020-02-03 Impact factor: 8.490
Authors: A Chernet; J Utzinger; V Sydow; N Probst-Hensch; D H Paris; N D Labhardt; A Neumayr Journal: Eur J Clin Microbiol Infect Dis Date: 2017-10-28 Impact factor: 3.267
Authors: Philippe Gautret; Frank P Mockenhaupt; Frank von Sonnenburg; Camilla Rothe; Michael Libman; Kristina Van De Winkel; Emmanuel Bottieau; Martin P Grobusch; Davidson H Hamer; Douglas H Esposito; Philippe Parola; Patricia Schlagenhauf Journal: Emerg Infect Dis Date: 2015-10 Impact factor: 6.883
Authors: Stefanie Knopp; Ali F Mgeni; I Simba Khamis; Peter Steinmann; J Russell Stothard; David Rollinson; Hanspeter Marti; Jürg Utzinger Journal: PLoS Negl Trop Dis Date: 2008-11-04
Authors: Julie Hoermann; Esther Kuenzli; Carmen Schaefer; Daniel H Paris; Silja Bühler; Peter Odermatt; Somphou Sayasone; Andreas Neumayr; Beatrice Nickel Journal: PLoS Negl Trop Dis Date: 2022-05-27
Authors: Pytsje T Hoekstra; Afona Chernet; Claudia J de Dood; Eric A T Brienen; Paul L A M Corstjens; Niklaus D Labhardt; Beatrice Nickel; Linda Wammes; Govert J van Dam; Andreas Neumayr; Lisette van Lieshout Journal: Am J Trop Med Hyg Date: 2022-02-28 Impact factor: 2.345